LB Pharmaceuticals Inc(LBRX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LBRX LB Pharmaceuticals Inc

交易中 10-08 12:18:56 EDT

33.84

-0.32

-0.94%

最高34.11	最低33.13	成交量11.72万
今开33.83	昨收34.16	日振幅2.87%
总市值10.92亿	流通市值7.32亿	总股本3,226万
成交额395.73万	换手率0.54%	流通股本2,162万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LBRX","market":"US","secType":"STK","nameCN":"LB Pharmaceuticals Inc","latestPrice":33.84,"timestamp":1791476322105,"preClose":34.16,"halted":0,"volume":117191,"delay":0,"changeRate":-0.00936768149882884,"floatShares":21621800,"shares":32259175,"eps":-2.988,"marketStatus":"交易中","change":-0.32,"latestTime":"10-08 12:18:56 EDT","open":33.83,"high":34.11,"low":33.13,"amount":3957292.79699,"amplitude":0.028689,"askPrice":33.91,"askSize":1,"bidPrice":33.71,"bidSize":25,"shortable":3,"etf":0,"ttmEps":-2.988,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1791489600000},"marketStatusCode":2,"adr":0,"listingDate":1757563200000,"exchange":"NASDAQ","adjPreClose":34.16,"preHourTrading":{"tag":"盘前","latestPrice":33.48,"preClose":34.16,"latestTime":"09:09 EDT","volume":410,"amount":13726.8,"timestamp":1791464948535,"change":-0.68,"changeRate":-0.019906,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":34.16,"preClose":34.16,"latestTime":"19:30 EDT","volume":5994,"amount":204755.04,"timestamp":1791415801549,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.682907,"impliedVol":0.6055,"impliedVolPercentile":0.1957},"requestUrl":"/m/hq/s/LBRX","defaultTab":"news","newsList":[{"id":"1132764548","title":"新闻稿：LB Pharmaceuticals任命Susan G. Kozauer医学博士担任首席医疗官","url":"https://stock-news.laohu8.com/highlight/detail?id=1132764548","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132764548?lang=zh_cn&edition=full","pubTime":"2026-09-15 20:01","pubTimestamp":1789473666,"startTime":"0","endTime":"0","summary":"纽约，2026年9月15日——专注于开发并商业化针对未得到充分治疗的脑部疾病多维度高影响力疗法的神经药物公司LB Pharmaceuticals Inc今日宣布，任命Susan G. Kozauer医学博士为首席医疗官。在Intra-Cellular Therapies, Inc.任职期间，Kozauer博士负责监督多种化合物的临床开发，包括CAPLYTA在成人和儿童适应症中的美国及全球后期开发。Kozauer博士最近担任礼来公司全资子公司Centessa Pharmaceuticals的高级副总裁兼临床开发主管，负责其食欲素激动剂产品组合的临床开发和战略。\"我很荣幸加入LB Pharmaceuticals团队，领导LB-102的临床开发。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128599574","title":"新闻稿：LB Pharmaceuticals任命Joseph Miller为首席财务官","url":"https://stock-news.laohu8.com/highlight/detail?id=1128599574","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128599574?lang=zh_cn&edition=full","pubTime":"2026-09-03 20:01","pubTimestamp":1788436892,"startTime":"0","endTime":"0","summary":"纽约，2026年9月3日——专注于开发并商业化针对未被充分满足的脑部疾病的多维度高影响力疗法的神经医学公司LB Pharmaceuticals Inc今日宣布，任命Joseph Miller为首席财务官。\"在接近NOVA-2数据读出这一我们下一阶段增长的关键里程碑之际，LB Pharmaceuticals已经建立了非凡的发展势头。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LBRX","MLR","BK4149"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151715449","title":"LB Pharmaceuticals 双相抑郁症II期Illuminate-1试验顶线数据预计于2028年第一季度公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1151715449","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151715449?lang=zh_cn&edition=full","pubTime":"2026-07-22 20:04","pubTimestamp":1784721854,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals Inc 宣布，其针对双相抑郁症的II期临床试验Illuminate-1的顶线数据，预计将在2028年第一季度获得。这一关键时间点的披露，将有助于市场评估该药物候选品的临床潜力与未来开发前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LBRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112760623","title":"LB制药宣布Lb-102精神分裂症三期Nova-2试验顶线结果加速揭晓","url":"https://stock-news.laohu8.com/highlight/detail?id=1112760623","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112760623?lang=zh_cn&edition=full","pubTime":"2026-07-22 20:02","pubTimestamp":1784721757,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals Inc  宣布，其针对精神分裂症的在研药物Lb-102，其关键性三期临床试验的顶线结果揭晓时间将比原计划提前。Nova-2试验是评估Lb-102疗效与安全性的关键一步，其结果将直接影响该药物的未来审批前景与商业潜力。公司此次主动调整时间表，通常被市场解读为对试验进展持有信心的信号。对于深耕中枢神经系统疾病领域的LB Pharmaceuticals而言，Lb-102是其研发管线中的重要资产，此次试验的加速推进无疑将吸引更多目光聚焦于公司的后续发展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LBRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114125454","title":"新闻稿：LB Pharmaceuticals 根据纳斯达克上市规则 5635(c)(4) 向新员工授予激励性股权奖励","url":"https://stock-news.laohu8.com/highlight/detail?id=1114125454","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114125454?lang=zh_cn&edition=full","pubTime":"2026-07-11 04:44","pubTimestamp":1783716299,"startTime":"0","endTime":"0","summary":"2026年7月10日，LB Pharmaceuticals Inc宣布，已根据纳斯达克上市规则5635的“激励性授予”例外条款，向新任临床运营高级副总裁Christopher Zergebel授予了一项股权奖励。该奖励旨在作为Zergebel先生加入公司任职的重要激励。此次授予的股权奖励虽在LB Pharmaceuticals Inc 2025年股权激励计划之外进行，但仍受其条款与条件约束。Zergebel先生获得了一项购买75,000股LB Pharmaceuticals普通股的期权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4233","FTEC","QQQJ","NDX","TQQY",".IXIC","IYW","QDTE","JEPQ","QQQ","TQQQ","NQmain","MNQmain","ONEQ","SQQQ","QYLG","QQQA","LB","QID","BK4007","QQQE","BK4213","GPIQ","LBRX","QLD","NVIW.SI","QQQY","TECS","PSQ","QQQM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113773800","title":"新闻稿：LB Pharmaceuticals任命Christopher Zergebel为临床运营高级副总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=1113773800","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113773800?lang=zh_cn&edition=full","pubTime":"2026-06-30 20:04","pubTimestamp":1782821050,"startTime":"0","endTime":"0","summary":"纽约，2026年6月30日——专注于开发精神分裂症、双相抑郁、重度抑郁症辅助治疗及其他神经精神疾病新型疗法的后期生物制药公司LB Pharmaceuticals Inc今日宣布，任命Christopher Zergebel为临床运营高级副总裁。在加入LB Pharmaceuticals之前，Zergebel先生曾担任Cellectis Biologics的开发运营副总裁，负责领导从早期到批准后试验的全球临床开发战略与运营。Zergebel先生持有波士顿大学生物学学士学位。本新闻稿中包含的所有前瞻性声明仅代表其发布之日的情况。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LB","BK4007","LBRX","BK4233","BK4213"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118992301","title":"LB Pharmaceuticals公布LB-102治疗精神分裂症二期NOVA-1试验结果获《JAMA Psychiatry》刊载","url":"https://stock-news.laohu8.com/highlight/detail?id=1118992301","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118992301?lang=zh_cn&edition=full","pubTime":"2026-04-23 04:06","pubTimestamp":1776888376,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals公司宣布，其针对精神分裂症治疗的创新药物LB-102二期临床试验NOVA-1的研究成果，已正式发表于国际权威期刊《美国医学会精神病学杂志》（JAMA Psychiatry）。该论文的刊登标志着该药物临床数据获得学界认可，为后续研发提供重要学术支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LBRX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lbpharma.us","stockEarnings":[{"period":"1week","weight":-0.11},{"period":"1month","weight":-0.3077},{"period":"3month","weight":0.0124},{"period":"6month","weight":0.4035},{"period":"1year","weight":1.1337},{"period":"ytd","weight":0.5346}],"compareEarnings":[{"period":"1week","weight":0.0191},{"period":"1month","weight":0.0091},{"period":"3month","weight":0.0339},{"period":"6month","weight":0.1439},{"period":"1year","weight":0.1616},{"period":"ytd","weight":0.1398}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"LB Pharmaceuticals Inc于2015年9月根据特拉华州法律注册成立。该公司是一家临床阶段的生物制药公司，开发用于治疗精神分裂症、双相抑郁症和其他神经精神疾病的新疗法。","exchange":"NASDAQ","name":"LB Pharmaceuticals Inc","nameEN":"LB Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"LB Pharmaceuticals Inc(LBRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供LB Pharmaceuticals Inc(LBRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"LB Pharmaceuticals Inc,LBRX,LB Pharmaceuticals Inc股票,LB Pharmaceuticals Inc股票老虎,LB Pharmaceuticals Inc股票老虎国际,LB Pharmaceuticals Inc行情,LB Pharmaceuticals Inc股票行情,LB Pharmaceuticals Inc股价,LB Pharmaceuticals Inc股市,LB Pharmaceuticals Inc股票价格,LB Pharmaceuticals Inc股票交易,LB Pharmaceuticals Inc股票购买,LB Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"LB Pharmaceuticals Inc(LBRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供LB Pharmaceuticals Inc(LBRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}